Kailera Therapeutics is trading at $19.91 (15%) up in after-hours sessions, extending its earlier pre-market strength amid a broad risk-on tone and strong index gains.
- The stock is continuing its rebound from late July levels as investors add exposure to higher-beta names.
- The upward move appears driven by market-wide sentiment and index performance rather than new company-specific news.